| Attribute |
Value |
| 52 Week Change |
-0.78539824 |
| Address1 |
MATAM Advanced Technology Park |
| Address2 |
Building No. 5 |
| All Time High |
30,400.0 |
| All Time Low |
0.85 |
| Ask |
1.16 |
| Ask Size |
1 |
| Average Daily Volume10 Day |
16,180 |
| Average Daily Volume3 Month |
23,781 |
| Average Volume |
23,781 |
| Average Volume10Days |
16,180 |
| Beta |
0.685 |
| Bid |
1.57 |
| Bid Size |
3 |
| Book Value |
-2.128 |
| City |
Haifa |
| Compensation As Of Epoch Date |
1,798,675,200 |
| Country |
Israel |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
0.94 |
| Current Ratio |
0.267 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
0.96 |
| Day Low |
0.9102 |
| Display Name |
Pluri |
| Dividend Date |
1,564,012,800 |
| Dividend Yield |
0.0 |
| Earnings Timestamp End |
1,758,571,200 |
| Earnings Timestamp Start |
1,758,052,800 |
| Ebitda |
-24,427,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-1.814 |
| Enterprise To Revenue |
43.618 |
| Enterprise Value |
44,316,052 |
| Eps Forward |
-1.9 |
| Eps Trailing Twelve Months |
-2.44 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.3476 |
| Fifty Day Average Change |
-0.4076 |
| Fifty Day Average Change Percent |
-0.30246362 |
| Fifty Two Week Change Percent |
-78.539825 |
| Fifty Two Week High |
4.87 |
| Fifty Two Week High Change |
-3.9299998 |
| Fifty Two Week High Change Percent |
-0.8069815 |
| Fifty Two Week Low |
0.85 |
| Fifty Two Week Low Change |
0.089999974 |
| Fifty Two Week Low Change Percent |
0.10588232 |
| Fifty Two Week Range |
0.85 - 4.87 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,056,979,800,000 |
| Float Shares |
6,124,964 |
| Forward Eps |
-1.9 |
| Forward P E |
-0.49473685 |
| Free Cashflow |
-12,096,750 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
92 |
| Fullday Change |
-0.029900014 |
| Fullday Change Percent |
-3.0827935 |
| Fullday Price |
0.94 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.44587 |
| Gross Profits |
453,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.42521 |
| Held Percent Institutions |
0.20683001 |
| Implied Shares Outstanding |
12,611,335 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,782,777,600 |
| Last Split Date |
1,711,929,600 |
| Last Split Factor |
1:8 |
| Long Business Summary |
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. |
| Long Name |
Pluri Inc. |
| Market |
us_market |
| Market Cap |
11,854,655 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_6124664 |
| Most Recent Quarter |
1,782,777,600 |
| Name Change Date |
2,026-10-14 |
| Net Income To Common |
-23,821,000 |
| Next Fiscal Year End |
1,814,313,600 |
| Non Diluted Market Cap |
13,085,420 |
| Open |
0.9594 |
| Operating Cashflow |
-19,588,000 |
| Operating Margins |
-16.55522 |
| Payout Ratio |
0.0 |
| Phone |
972 74 710 8600 |
| Prev Name |
Pluristem Therapeutics Inc. |
| Previous Close |
0.9699 |
| Price Hint |
4 |
| Price To Book |
-0.4417293 |
| Price To Sales Trailing12 Months |
11.667968 |
| Profit Margins |
0.0 |
| Quick Ratio |
0.245 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.029900014 |
| Regular Market Change Percent |
-3.0827935 |
| Regular Market Day High |
0.96 |
| Regular Market Day Low |
0.9102 |
| Regular Market Day Range |
0.9102 - 0.96 |
| Regular Market Open |
0.9594 |
| Regular Market Previous Close |
0.9699 |
| Regular Market Price |
0.94 |
| Regular Market Time |
1,791,921,600 |
| Regular Market Volume |
14,916 |
| Return On Assets |
-0.49043 |
| Revenue Growth |
-0.158 |
| Revenue Per Share |
0.104 |
| Sand P52 Week Change |
0.17502642 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
12,611,335 |
| Shares Percent Shares Out |
0.0016 |
| Shares Short |
19,310 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
26,450 |
| Short Name |
Pluri Inc. |
| Short Percent Of Float |
0.0029 |
| Short Ratio |
0.97 |
| Source Interval |
15 |
| Symbol |
PLUR |
| Total Cash |
7,804,000 |
| Total Cash Per Share |
0.632 |
| Total Debt |
34,914,000 |
| Total Revenue |
1,016,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-2.44 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
2.5254 |
| Two Hundred Day Average Change |
-1.5853999 |
| Two Hundred Day Average Change Percent |
-0.6277817 |
| Type Disp |
Equity |
| Volume |
14,916 |
| Website |
https://www.pluri-biotech.com |
| Zip |
3,508,409 |